Literature DB >> 9120919

Collagen injection therapy for female intrinsic sphincteric deficiency.

D N Smith1, R A Appell, J C Winters, R R Rackley.   

Abstract

PURPOSE: Since glutaraldehyde cross-linked collagen was approved for use, studies have reported success or improved rates of 63 to 86%. Long-term efficacy with strictly defined outcome criteria has not been reported. We report our experience with collagen injection therapy for female patients with intrinsic sphincteric deficiency to establish efficacy, duration of response and clinical predictors of success.
MATERIALS AND METHODS: A total of 96 women underwent collagen injection via a periurethral approach with local anesthesia. In all patients history, physical examination and video urodynamics documented intrinsic sphincteric deficiency without urethral hypermobility. Continence success was defined as dry or socially continent (minimal leakage requiring 1 or no pad daily even with strenuous activity). Median followup was 14.0 months.
RESULTS: Of 94 patients 67.0% achieved continence, 38.3% became dry and 28.7% became socially continent. Of 35 patients who achieved continence with at least 1 year of followup 6 had regression. Therefore, 82.9% of those successfully treated remained so at 1 year and none had de novo detrusor instability. An average of 2.1 procedures and 11.9 ml. collagen were required to achieve continence. The 31 patients not achieving success underwent an average of 3.2 procedures with 16.1 ml. collagen. No major complications have occurred to date.
CONCLUSIONS: Collagen injection achieves a reasonable rate of continence and good durability at 1 year of followup in female patients with intrinsic sphincteric deficiency and no urethral hypermobility.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9120919

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

1.  Tegresstrade mark Urethral Implant Phase III Clinical Experience and Product Uniqueness.

Authors:  Roger R Dmochowski
Journal:  Rev Urol       Date:  2005

2.  Current use of injectable agents for female stress urinary incontinence.

Authors:  Sender Herschorn
Journal:  Rev Urol       Date:  2005

Review 3.  Pubovaginal slings: past, present and future.

Authors:  R Sarver; F E Govier
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1997

4.  Sling and bulking agent placement procedures.

Authors:  Alfred E Bent
Journal:  Rev Urol       Date:  2004

5.  Treatment options for stress urinary incontinence.

Authors:  Eric S Rovner; Alan J Wein
Journal:  Rev Urol       Date:  2004

Review 6.  Stress urinary incontinence in women.

Authors:  Pejvak Sassani; Sherif R Aboseif
Journal:  Curr Urol Rep       Date:  2009-09       Impact factor: 3.092

7.  Long-term subjective continence status and use of alternative treatments by women with stress urinary incontinence after collagen injection therapy.

Authors:  Kyoko Sakamoto; Sameer Sharma; John S Wheeler
Journal:  World J Urol       Date:  2007-06-26       Impact factor: 4.226

Review 8.  A transperitoneal laparoscopic approach to endourology.

Authors:  A M Kaynan; H N Winfield
Journal:  Curr Urol Rep       Date:  2001-04       Impact factor: 2.862

Review 9.  Use of collagen for the treatment of stress urinary incontinence: an update.

Authors:  M B Tchetgen; R A Appell
Journal:  Curr Urol Rep       Date:  2000-10       Impact factor: 2.862

Review 10.  Injectable agents: present and future.

Authors:  Deborah J Lightner; Nancy B Itano; Susan D Sweat; Kristin L Chrouser; Felecia Fick
Journal:  Curr Urol Rep       Date:  2002-10       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.